Bioceres Crop Solutions (BIOX) to Release Earnings on Wednesday

Bioceres Crop Solutions (NASDAQ:BIOX) is expected to issue its Q3 2025 quarterly earnings data before the market opens on Wednesday, June 4th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $61.87 million for the quarter.

Bioceres Crop Solutions (NASDAQ:BIOX) last released its quarterly earnings data on Wednesday, May 21st. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. Bioceres Crop Solutions had a return on equity of 0.68% and a net margin of 0.58%. The company had revenue of $59.60 million during the quarter, compared to the consensus estimate of $61.80 million. On average, analysts expect Bioceres Crop Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioceres Crop Solutions Stock Performance

Bioceres Crop Solutions stock opened at $5.16 on Wednesday. The business has a 50 day moving average of $4.37 and a 200-day moving average of $5.45. Bioceres Crop Solutions has a 1 year low of $3.51 and a 1 year high of $11.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.33 and a quick ratio of 0.96. The company has a market capitalization of $323.59 million, a P/E ratio of 258.13 and a beta of 0.40.

Hedge Funds Weigh In On Bioceres Crop Solutions

A hedge fund recently raised its stake in Bioceres Crop Solutions stock. Bank of America Corp DE increased its position in Bioceres Crop Solutions Corp. (NASDAQ:BIOX) by 186.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,735 shares of the company’s stock after purchasing an additional 3,735 shares during the period. Bank of America Corp DE’s holdings in Bioceres Crop Solutions were worth $35,000 at the end of the most recent quarter. 17.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIOX has been the subject of several recent research reports. Lake Street Capital lowered their price objective on Bioceres Crop Solutions from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Oppenheimer reduced their target price on Bioceres Crop Solutions from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, April 22nd. Finally, Canaccord Genuity Group reduced their target price on Bioceres Crop Solutions from $7.00 to $6.50 and set a “buy” rating on the stock in a report on Thursday, February 13th. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Bioceres Crop Solutions presently has an average rating of “Buy” and a consensus target price of $8.63.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.